DDInter1642 DDInter612
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Sonidegib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Duvelisib may lead to a major life threatening interaction when taken with Sonidegib
Duvelisib may lead to a major life threatening interaction when taken with Upadacitinib